RSS Feeds
Effect of 9-(1,3-Dihydroxy-2-Propoxymethyl) Guanine on Serious Cytomegalovirus Disease in Eight Immunosuppressed Homosexual Men
- HENRY MASUR, M.D.;
- H. CLIFFORD LANE, M.D.;
- ALAN PALESTINE, M.D.;
- PHILLIP D. SMITH, M.D.;
- JODY MANISCHEWITZ, M.D.;
- GARTH STEVENS, M.D.;
- LESLIE FUJIKAWA, M.D.;
- ABE M. MACHER, M.D.;
- ROBERT NUSSENBLATT, M.D.;
- BARBARA BAIRD, R.N.;
- MARGARET MEGILL, R.N.;
- ALEC WITTEK, M.D.;
- GERALD V. QUINNAN, M.D.;
- JOSEPH E. PARRILLO, M.D.;
- ALAIN H. ROOK, M.D.;
- LAWRENCE J. ERON, M.D.;
- DONALD M. PORETZ, M.D.;
- ROBIN I. GOLDENBERG, M.D.;
- ANTHONY S. FAUCI, M.D.; and
- EDWARD P. GELMANN, M.D.
Abstract
Eight immunosuppressed homosexual men with cytomegalovirus viremia—seven with serious bilateral retinitis, one with colitis in addition to retinitis, and one with pneumonitis only—were treated with a new acyclovir derivative, 9-(1,3-dihydroxy-2-propoxymethyl) guanine, which has excellent in-vitro activity against cytomegalovirus. All patients had virologic and clinical improvement, but substantial leukopenia developed in three patients. Both clinical relapses and viral relapses occurred frequently, usually within 30 days after cessation of treatment. 9-(1,3-Dihydroxy-2-propoxymethyl) guanine represents the first clinically and virologically effective agent for the treatment of cytomegalovirus disease, but more effective and less toxic therapeutic regimens for both acute and chronic use must be developed.
Article and Author Information
-
▸From the Clinical Center, National Institute of Allergy and Infectious Diseases, National Eye Institute, and National Cancer Institute, National Institutes of Health; and the Division of Virology, Food and Drug Administration, Bethesda, Maryland; and Fairfax Hospital, Falls Church, Virginia.
-
▸Requests for reprints should be addressed to Henry Masur, M.D.; Clinical Center, Building 10, Room 10D-48, National Institutes of Health; Bethesda, MD 20205.
